Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAtlantic Lithium Regulatory News (ALL)

Share Price Information for Atlantic Lithium (ALL)

Share Price is delayed by 15 minutes
Get Live Data
16.35    -0.10 (-0.61%)
Bid:
16.30
Ask:
16.45
Spread: 0.15 (0.92%)
Market Cap: £131.05m
ALL Live PriceLast checked at - London Stock Exchange

Intraday Atlantic Lithium Share Chart

Full Year Trading Update

26 Jun 2012 07:00

RNS Number : 1056G
Allocate Software PLC
26 June 2012
 



ALLOCATE SOFTWARE PLC

("Allocate" or "the Company")

 

 

Full Year Trading Update

 

Allocate Software (AIM: ALL), the leading provider of workforce and compliance optimisation solutions, announces an update on trading for its financial year ended 31 May 2012. The Company's final results will be announced in the week commencing 30 July 2012.

 

Highlights

 

§ Strong financial performance in the year with results expected to be in line with market expectations.

 

§ Healthcare had another successful year securing new customers across the NHS, in the UK private healthcare sector and overseas.

 

§ Completed two acquisitions in the financial year: Zircadian in the UK and RosterOn in Australia. Both performed in line with expectations and the cross-sell of different products into the customer base is beginning to yield encouraging results.

 

§ Defence had a record year, with major contract wins worldwide including the multi million pound agreement with the Australian Defence Forces.

 

Healthcare

 

Because of the drive in the NHS for efficiency and cost savings, market appetite for the Allocate application suite with its proven ROI remained strong, with new customers, new products, licence renewals and extensions. HealthRoster, our e-rostering product, retained its strong competitive position and was selected in the majority of all competitive tenders in the UK during the fiscal year.

 

The release of v10, the fully web-based version of HealthRoster with multi-language capability, positions this product well for further internationalisation. Our Swedish business, Time Care, has again performed well and met expectations as it has now done every year since acquisition. HealthRoster will be available in Swedish as the first internationalisation of HealthRoster in the coming months.

 

Leveraging acquisitions - the integration of HealthRoster and the Zircadian products with the rest of the Allocate suite of products provides customers with an end to end solution from planning to scheduling of the medical workforce. In addition, the integration of HealthRoster and the RosterOn product has created a bespoke leading employment awards interpretation engine for the Australian market. The broadening of our product range is creating significant cross-sell opportunities, in line with our strategy.

 

Defence

 

The Defence business achieved substantial growth and continued diversifying into other geographic regions, generating significant business from overseas. Highlights include:

 

§ Securing a multi-million pound licence contract with the Australian Defence Department extending the use of Defence Suite across the Army, Navy and civilians under military control.

§ Substantial additional Consultancy Services contract extension wins with the Royal Australian Navy, as part of their New Generation Navy programme.

§ Two new Consultancy Services contract wins in NATO within their Force Operations Group, and Special Forces HQ.

§ Extension of the UK Army Support contract to 2014

 

Maritime

 

§ Secured a new licence agreement with McDermott Inc, a major US offshore engineering company, the third in this sector

§ Completed a major Maritime Suite implementation to support SubSea7's global Offshore Oil Services operations

 

 

Ian Bowles, Chief Executive Officer of Allocate commented: "Despite the global economic environment and the macro economics of UK government spending we have executed well in our industry sectors and I am delighted with the performance of Allocate this year, particularly in the second half.

 

"2012 was our sixth consecutive year of record revenue. This consistency of execution, I believe, demonstrates a balance across our business, both in terms of vertical markets and geographical focus, which speaks well to our plans for significant growth over the next three to five years. I am very pleased with this year's performance and look forward to Allocate's continued success in the next financial year".

 

 

Enquiries:

Allocate Software plc

Ian Bowles - Chief Executive Officer

Chris Gale - Chief Financial Officer

Martin Jeffries - Marketing Director

 

Tel: +44 (0) 20 7355 5555

Numis Securities

Nominated adviser - Michael Meade / Simon Willis/ Richard Thomas

Corporate Broking - James Black

 

Tel: +44 (0) 20 7260 1000

Gable Communications

Justine James / John Bick

 

Tel: +44 (0) 20 7193 7463

M: +44 (0) 7525 324431

 

About Allocate Software plc

Allocate Software plc is the leading workforce optimisation software applications provider for world-wide organisations with large, multi-skilled workforces. With a blue chip client base spanning the public and private sector, its key vertical markets include: Healthcare and Defence.

 

At the core of the business is Allocate's workforce optimisation software, which organisations use to deploy the right people with the right skills, to the right place at the right time. Headquartered in London, Allocate provides services and support to its increasing international customer base through regional offices in the UK, Sweden, USA, Australia and Malaysia.

 

Allocate is quoted on the London Stock Exchange (AIM: ALL). For further information please visit www.allocatesoftware.com.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUVRNRUOANUAR
Date   Source Headline
23rd Nov 20239:39 amRNSUpdated Quarterly Activities and Cash Flow Report
22nd Nov 20237:00 amRNSProject Development Update
16th Nov 20237:00 amRNSInvestor Presentation - Noosa Mining Conference
15th Nov 20237:00 amRNSRejection of Non-Binding Indicative Offers
14th Nov 20237:00 amRNSGrant of Highly Prospective Licences for Lithium
10th Nov 20237:00 amRNSConference Attendance
7th Nov 20237:00 amRNSAdditional Resource Extension Drilling Planned
1st Nov 20237:00 amRNSChange of Registered Office
31st Oct 20237:05 amRNSNotice of AGM
31st Oct 20237:00 amRNSQuarterly Activities and Cash Flow Report
20th Oct 20237:00 amRNSMining Lease Granted for Ewoyaa Lithium Project
19th Oct 202311:35 amRNSStatement re Media Speculation
13th Oct 20237:00 amRNSConference Attendance
10th Oct 20237:00 amRNSApproval to Divert Transmission Lines at Ewoyaa
29th Sep 20239:55 amRNSInvestor Presentation
28th Sep 20237:00 amRNS2023 Annual Financial Report
21st Sep 20237:00 amRNSNotice of Results and Investor Presentation
15th Sep 20237:00 amRNSConference Attendance
8th Sep 20237:05 amRNSInvestor Presentation
8th Sep 20237:00 amRNSUS$32.9m Strategic Investment
6th Sep 20237:00 amRNSResource and Exploration Drilling Results
4th Sep 20238:45 amRNSConference Attendance
30th Aug 20237:00 amRNSIssue of Equity - ESOP Options
22nd Aug 20237:00 amRNSIssue of Equity - Exercise of ESOP Options
17th Aug 20237:00 amRNSPartner Commits to Ewoyaa Development Funding
15th Aug 20237:00 amRNSMOU Signed for By-product Feldspar Study
10th Aug 20239:14 amRNSPCA Dealings
9th Aug 20239:30 amRNSDirector/PDMR Dealings
8th Aug 20237:00 amRNSResource and Exploration Drilling Results
7th Aug 20233:13 pmRNSStatement re Media Speculation
31st Jul 20237:00 amRNSQuarterly Activities and Cash Flow Report
19th Jul 20237:00 amRNSConference Attendance
13th Jul 20237:00 amRNSAppointment of Flotation Scoping Study Partner
30th Jun 20237:00 amRNSInvestor Presentation
29th Jun 20238:21 amRNSEwoyaa Definitive Feasibility Study
29th Jun 20237:17 amRNSEwoyaa Definitive Feasibility Study
23rd Jun 202311:00 amRNSBoard Appointments
20th Jun 20237:00 amRNSInitial Infill Drilling Results
16th Jun 20237:00 amRNSConference Attendance
13th Jun 20237:00 amRNSCorporate Update - Resignation of Director
1st Jun 20237:00 amRNSBoard Changes
26th May 20237:00 amRNSDTC Eligibility for OTCQX Electronic Trading
17th May 20237:00 amRNSConference Attendance
16th May 20237:00 amRNSAppointment of Chief Executive Officer
4th May 20237:00 amRNSConference Attendance
28th Apr 20237:00 amRNSQuarterly Activities and Cash Flow Report
26th Apr 20237:00 amRNSInternational Lithium Association Membership
19th Apr 20237:00 amRNSInfill Drilling and Passive Seismic Survey
6th Apr 20237:00 amRNSIssue of Equity – Exercise of ESOP Options
31st Mar 20237:00 amRNSIssue of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.